Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

South and Southeast Asia map, showing locations of artemisinin-resistant Plasmodium falciparum malaria in Asia © 2022. Courtesy of The Lancet Microbe.

26 January 2022 - Published in the Lancet Microbe, the study, Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia, aimed to develop up-to-date spatial distribution visualisations of the 'WHO-validated' Kelch-13 (K13) markers of artemisinin resistance to guide policy decisions. Researchers collated data from 72 studies published between 1 January 2010 and 31 March 2021, comprising K13 markers from 16,613 blood samples collected from 1991 to 2020 from 18 countries.

They found a steady increase in the prevalence of 'WHO-validated' K13 markers, reaching 62∙9 per cent in 2018. Overall, the prevalence of C580Y mutation increased to 84∙9 per cent in 2018 from 48∙9 per cent in 2002. Data showed that from 2002 to 2018, there has been a steady increase in geographic locations and the proportion of infected people with 'validated' artemisinin resistance markers.

First identified in Cambodia’s Battambang and Pailin provinces on the border with Thailand, then identified in Cambodia, Myanmar and Thailand in 2009, these validated and associated mutations are now found in six additional countries (China, India, Laos, Papua New Guinea, Saudi Arabia, and Vietnam). Thus, increases in the prevalence and extent of WHO-validated or WHO-associated markers over time were seen in Myanmar, Thailand, Cambodia, Vietnam, Laos and, to a lesser extent, in China.

The emergence and spread of artemisinin and artemisinin-based combination therapy (ACT) partner drug resistance in the Greater Mekong Subregion (GMS) poses a significant threat to global efforts to eliminate malaria and with the potential to spread or emerge further afield, including to India, Africa and Latin America, and highlights its immediate relevance to Africa, say the researchers. 

Worryingly, a recent report in the NE Journal of Medicine showed independent emergence and local spread of clinically artemisinin-resistant P. falciparum in Africaand an editorial in the American Journal of Tropical Medicine and Hygiene asked if artemisin-based combination therapies were beginning to fail in Africa.

This is the first study to use the 2020 revised WHO classification for K13 markers and the first to aggregate all published K13 marker data in Asia and map them by province and district. It highlights that non-uniform, patchy and delayed reporting are crucial challenges in K13 surveillance.

Currently, data in the literature are reported in an unstructured way leading to difficulties in pooling and interpretation. Researchers conclude that more consistent data collection over extended periods in the same areas with the rapid sharing of data are needed to map the spread and evolution of resistance to better inform policy decisions. A tool, developed by scientists from WWARN, Mahidol-Oxford Tropical Medicine Research Unit (MORU) and the University of Cape Town (UCT), with a set of minimum criteria for reporting future studies can overcome this issue, researchers say.

Read the full paper:

Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Frank M Kagoro, Karen I Barnes, Kevin Marsh, Nattwut Ekapirat, Chris Erwin G Mercado, Ipsita Sinha, Georgina Humphreys, Mehul Dhorda, Philippe J Guerin, Richard J Maude. www.thelancet.com/microbe Published online January 25, 2022 https://doi.org/10.1016/S2666-5247(21)00249-4

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.